CD19 and acute lymphoblastic leukemia: ,101 The feasibility of clinical implementation of such a strategy was illustrated by a study in which two therapy-refractory pediatric patients with acute lymphoblastic leukemia (ALL) were treated with allogeneic anti-CD19 CAR-T cells from unselected donors102 that had been engineered in vitro using TALENs in two ways.